AG-348: Preliminary Phase I data

Preliminary data from 16 healthy volunteers in the first 2 cohorts of a double-blind, placebo-controlled, U.S. Phase I trial showed that twice-daily 120 and 360 mg doses of oral AG-348 for 14 days wer...